Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.
Morning, all. Today, we have more interesting tidbits from the STAT Summit: Eli Lilly’s CSO defends the company’s hiring of former FDA official Peter Marks, biotech CEOs warn that FDA turmoil is already affecting drug pipelines, and more.
Oh, and if you’re not already a STAT+ subscriber, check out a new promotion.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply